<style>
ul.experts li {
	width: 47%;
}

</style>

<p>This independent medical education activity features  an expert interview  with <strong>Robert E. Coleman, MD, FRCP, FRCE</strong>;<strong> </strong><strong>Peter Dubsky, MD</strong><em>; </em>and <strong>Aleix Prat, MD, PhD</strong>, focusing  on the role of novel gene expression profiles  in patients with early breast cancer.</p>
<p>Professors Coleman, Dubsky, and Prat discuss  the following recent publications: 
</p>
    <p><a href="http://www.ncbi.nlm.nih.gov/pubmed/24625003" target="_blank" style="font-weight: bold; font-style:italic; color: #000; text-decoration: none;">Analytical validation of the  PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter  Analysis System using formalin-fixed paraffin-embedded breast tumor specimens<br>
    <strong>&nbsp;Nielsen T, et al.<em> BMC Cancer.</em> 2014;14:177.</strong></a><strong></strong></p>
    <p><strong><em><a href="http://www.ncbi.nlm.nih.gov/pubmed/24347518" target="_blank" style="font-weight: bold; font-style:italic; color: #000; text-decoration: none;">Predicting distant recurrence in receptor-positive breast cancer patients  with limited clinicopathological risk: Using the PAM50 Risk of Recurrence score  in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant  endocrine therapy alone</a></em></strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/24347518" style="font-weight: bold; font-style:italic; color: #000; text-decoration: none;"><br>
<strong>Gnant  M, et al.&nbsp; <em>Ann Oncol.</em> 2014;25(2):339-345</strong></a><strong>.</strong><strong></strong></p>
    <p><a href="http://www.ncbi.nlm.nih.gov/pubmed/24520097" target="_blank" style="font-weight: bold; font-style:italic; color: #000; text-decoration: none;">The  PAM50 risk-of-recurrence score predicts risk for late distant recurrence after  endocrine therapy in postmenopausal women with endocrine-responsive early  breast cancer<br>
    <strong>Filipits  M, et al. <em>Clin Cancer Res.</em> 2014;20(5):1298-1305.</strong></a></p>
    <p><a href="http://www.ncbi.nlm.nih.gov/pubmed/24029245" target="_blank" style="font-weight: bold; font-style:italic; color: #000; text-decoration: none;">Factors  predicting late recurrence for estrogen receptorâ€“positive breast cancer<br>
    <strong>Sestak  I, et al. <em>J Natl Cancer Inst.</em> 2013;105(19):1504-1511.</strong></a><strong></strong></p>
<p><a href="http://www.ncbi.nlm.nih.gov/pubmed/23816962" target="_blank" style="font-weight: bold; font-style:italic; color: #000; text-decoration: none;">Comparison  of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk  of distant recurrence after endocrine therapy<br>
  <strong>Dowsett M, et al. <em>J Clin Oncol.</em> 2013;31(22):2783-2790.</strong></a>
</p>
<div class="hr"></div>

<h3 class="color2">Featured Experts</h3>
<h6>MODERATOR</h6>
<ul class="experts clearfix">
<li>
    <div class="experts-photo"><img src="~/media/Images/Expert%20Photo/Coleman.ashx" alt="reig" width="80" height="100"></div>
    <div class="experts-details"><b>Robert E. Coleman</b><br>
      Medical Director<br>
    prIME Oncology</div>
</li>
</ul>

<h6>DISCUSSANTS</h6>
<ul class="experts clearfix">
<li>
    <div class="experts-photo"><img src="~/media/Images/Expert%20Photo/dubsky.ashx" alt="reig" width="80" height="100"></div>
    <div class="experts-details"><b>Peter Dubsky, MD</b><br>
      Medical University of Vienna<br>
    Vienna, Austria</div>
</li>
<li>
    <div class="experts-photo"><img src="~/media/Images/Expert%20Photo/prat.ashx" alt="reig" width="80" height="100"></div>
    <div class="experts-details"><b>Aleix Prat, MD, PhD</b><br>
      Hospital Clinic of Barcelona<br>
    Barcelona, Spain</div>
</li>
</ul>